cholesterol Archives -

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

Phil Taylor Amgen, AstraZeneca, cholesterol, Ionis Pharmaceuticals, Leqvio, Novartis, PCSK9 inhibitors, Praluent, Regeneron, Repatha, Sanofi 0 Comment

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

https://pharmaphorum.com/news/az-and-ionis-pcsk9-cholesterol-drug-will-not-move-to-phase-3/

News/ News/ R&D

NewAmsterdam goes public to advance drug in abandoned class

Phil Taylor cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D 0 Comment

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier

NewAmsterdam goes public to advance drug in abandoned class

https://pharmaphorum.com/news/newamsterdam-goes-public-to-advance-drug-in-abandoned-class/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

News/ News/ R&D

Verve starts trials of cholesterol drug in test of base editing technique

Phil Taylor cholesterol, CRISPR/Cas9, gene editing, heterozygous familial hypercholesterolaemia, Leqvio, PCSK9, Praluent, Repatha, Verve Therapeutics 0 Comment

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for

Verve starts trials of cholesterol drug in test of base editing technique

https://pharmaphorum.com/news/verve-starts-trials-of-cholesterol-drug-in-test-of-base-editing-technique/

News/ News/ Sales and Marketing

Novartis bags elusive US approval for cholesterol drug inclisiran

Phil Taylor Amgen, cholesterol, inclisiran, Leqvio, Novartis, PCSK9, Praluent, Regeneron, regulatory approval, Repatha, Sanofi 0 Comment

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce

Novartis bags elusive US approval for cholesterol drug inclisiran

https://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/

The critical role of the generics sector during the pandemic

News/ News/ R&D

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

Phil Taylor antisense drugs, cardiovascular, cholesterol, evinacumab, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/

News/ News/ R&D

Merck’s oral PCSK9 drug matches injectables in early trials

Phil Taylor Amgen, cholesterol, Merck & Co, Novartis, PCSK9, Regeneron, Sanofi 0 Comment

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck &

Merck’s oral PCSK9 drug matches injectables in early trials

https://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/

Market Access/ News/ News

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

Phil Taylor cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi 0 Comment

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

https://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/

Market Access/ News/ News

Novartis eyes New Year verdict from FDA on delayed Leqvio

Phil Taylor asciminib, cholesterol, fda, Leqvio, Novartis 0 Comment

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by

Novartis eyes New Year verdict from FDA on delayed Leqvio

https://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/

Market Access/ News/ News

Novartis tries to rescue stalled inclisiran filing with FDA

Phil Taylor Alnylam, cardiology, cholesterol, fda, inclisiran, Novartis 0 Comment

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on

Novartis tries to rescue stalled inclisiran filing with FDA

https://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/

Trending

cholesterol

Login